Eisai and Helsinn Healthcare have announced the availability of Aloxi (palonosetron hydrochloride) injection 0.075 mg for the prevention of postoperative nausea and vomiting. The FDA approved the drug on February 29, 2008.
Filed under: Uncategorized | Tagged: 5-HT3, 5HT3, Aloxi, antagonist, Eisai, Helsinn, Palonosetron | Leave a Comment »
Phase III data presented at the European Society of Human Reproduction and Embryology meeting show Schering-Plough’s FSH analog corifollitropin alpha to have met its primary endpoints
Filed under: gpcr | Tagged: FSH, phase III, Schering, Schering-Plough | Leave a Comment »
Emisphere have released Phase I data from a clinical study assessing the oral delivery of GLP-1 peptide. The delivery agent, SNAC, allowed for rapid oral absorption of GLP-1.
Filed under: gpcr | Tagged: Emisphere, GLP-1, phase I | Leave a Comment »
Sciele Pharma have completed a phase III trial for Glycopyrrolate Liquid for the treatment of chronic, moderate-to-severe drooling in pediatric patients
Filed under: Uncategorized | Tagged: antagonist, Glycopyrrolate, M3, Muscarinic, Muscarinic M3, phase III, Robinul, Sciele | Leave a Comment »
